Sandbox Reserved 687

From Proteopedia

Revision as of 20:43, 2 May 2013 by Student (Talk | contribs)
Jump to: navigation, search
This Sandbox is Reserved from 30/01/2013, through 30/12/2013 for use in the course "Biochemistry II" taught by Hannah Tims at the Messiah College. This reservation includes Sandbox Reserved 686 through Sandbox Reserved 700.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Complera: Emtricitabine/rilpivirine/tenofovir

  • Marketed by: Gilead Sciences and Janssen Therapeutics
  • Major Indication: HIV infection
  • Drug Class: Combination of nucleoside/tide reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor
  • Date of FDA Approval: August 2011



Rilpivirine (RPV)

Crystal structure of HIV-1 reverse transcriptase in complex with rilpivirine

Drag the structure with the mouse to rotate

RPV in the In red are the binding pocket residues p66 (Leu-100, Lys-101, Lys-103, Val-106, Thr-107, Val-108, Val-179, Tyr-181, Tyr-188, Val-189, Gly-190, Phe-227, Trp-229, Leu- 234, and Tyr-318) and p51(Glu-138). Singh et al.

Tenofovir Image:Tenofovir.png

HIV-1 reverse transcriptase crosslinked to tenofovir terminated template-primer

Drag the structure with the mouse to rotate

Reverse Transcriptase:

Emtricitabine Image:Emtricitabine3.png

Insert caption here

Drag the structure with the mouse to rotate
Retrieved from "http://52.214.119.220/wiki/index.php/Sandbox_Reserved_687"
Personal tools